1801 — Innovent Biologics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapHigh Flyer

Annual cashflow statement for Innovent Biologics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-859	-3,051	-2,170	-1,144	-78.6
Depreciation
Amortisation
Non-Cash Items	939	938	-312	389	542
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-474	-117	244	518	404
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-308	-2,025	-1,919	148	1,287
Capital Expenditures	-522	-1,848	-1,366	-1,382	-1,642
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-4,663	-851	-69.7	383	477
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-5,185	-2,698	-1,435	-999	-1,165
Financing Cash Flow Items	-88.6	-132	73.6	-54.6	39.5
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	4,912	5,003	2,892	2,587	-607
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-1,150	83.2	-343	1,730	-472